Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration.
Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical highlights interim data from retreatment trial appeared first on MassDevice.